Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Eritoran in Severe Sepsis
NCT00046072Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2001
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eritoran in sepsis (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Safety and Tolerability at 28 days. Started Oct 2001; status: completed.
02
Drugs
eritoran
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT00046072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046072.